Merck was awarded a separate patent for the use of finasteride to treat pattern hair loss and it expired in November 2013. The first study of finasteride in the treatment of hirsutism in women was published in 1994. However, the different isozymes of 5α-reductase appear to be widely expressed, with notable tissues including the prostate gland, seminal vesicles, testes, epididymides, skin, hair follicles, liver, kidneys, and brain, among others. An oral dosage of finasteride of only 0.2 mg/day has been found to achieve near-maximal suppression of DHT levels (68.6% for 0.2 mg/day relative to 72.2% for 5 mg/day). Study staff and participants were unaware of testosterone dose and whether they received dutasteride or placebo. A randomization table was used to allocate individuals to 1 of 8 study groups (placebo plus 50, 125, 300, or 600 mg/wk of testosterone enanthate intramuscularly for 20 weeks or 2.5 mg/d of dutasteride plus 50, 125, 300, or 600 mg/wk of testosterone enanthate intramuscularly for 20 weeks). The primary objective of this study was to determine whether 5α-reduction of testosterone to DHT is obligatory for mediating its effects on fat-free mass. Changes in fat mass, muscle strength, sexual function, prostate volume, sebum production, and hematocrit and lipid levels did not differ between groups. Athletes who used finasteride and were banned from international competition include skeleton racer Zach Lund, bobsledder Sebastien Gattuso, footballer Romário, and ice hockey goaltender José Théodore. From 2005 to 2009, the World Anti-Doping Agency banned finasteride because it was discovered that the drug could be used to mask steroid abuse. Rasmusson and Brooks were awarded IPO's "Inventor of the Year" award in 1993 for their work on finasteride. A team led by chemist Gary Rasmusson and biologist Jerry Brooks developed potential 5α-reductase inhibitors based on transition-state inhibitors, using an iterative process of molecular design, testing, and redesign. These children, despite being raised as girls until puberty, were generally heterosexual and were termed "Guevedoces" by their local community, which means "penis at twelve" in Spanish. In 1942, James Hamilton observed that prepubertal castration prevents the later development of male pattern baldness in mature men. While some of these hold weight in certain regards, they are totally irrelevant to androgenic alopecia most of the time, and focus entirely on temporary shedding misinterpreted as androgenic alopecia. There are a variety of interesting theories that have branched out attempting to make sense of hair loss in a context that explains why DHT isn’t the only factor at play here. There are a variety of genetic anomalies that are extremely rare, but exist nonetheless and can provide near immunity to hair loss progression. The only reason I did it was to truly establish Testosterone’s myotrophic-to-androgenic selectivity without DHT present for my future reference. In some men, sexual dysfunction may persist after stopping the medication. In addition to DHT, finasteride also inhibits the production of several anticonvulsant neurosteroids including allopregnanolone, androstanediol, and tetrahydrodeoxycorticosterone. It works by decreasing the production of dihydrotestosterone (DHT) by about 70%. There were no signifi-cant differences in the testosterone levels or the change in testosterone levels after treatment between the two groups. When analysed by baseline serum testosterone tertile, the increases in serum testosterone level among the dutasteride and combination group were greatest in the lowest tertile. Scalp DHT concentrations in the Dutasteride groups were significantly suppressed compared with placebo in a dose-related manner.
